135 related articles for article (PubMed ID: 16815402)
1. Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome.
Bourla DH; Laron Z; Snir M; Lilos P; Weinberger D; Axer-Siegel R
Ophthalmology; 2006 Jul; 113(7):1197.e1-5. PubMed ID: 16815402
[TBL] [Abstract][Full Text] [Related]
2. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.
Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2009 Jun; 19(3):280-2. PubMed ID: 19117781
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
4. Head circumference in untreated and IGF-I treated patients with Laron syndrome: comparison with untreated and hGH-treated children with isolated growth hormone deficiency.
Laron Z; Iluz M; Kauli R
Growth Horm IGF Res; 2012 Apr; 22(2):49-52. PubMed ID: 22414926
[TBL] [Abstract][Full Text] [Related]
5. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne.
Ben-Amitai D; Laron Z
J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):950-4. PubMed ID: 21054577
[TBL] [Abstract][Full Text] [Related]
6. Eyes of a lower vertebrate are susceptible to the visual environment.
Shen W; Sivak JG
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4829-37. PubMed ID: 17898310
[TBL] [Abstract][Full Text] [Related]
7. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
8. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome.
Konen O; Silbergeld A; Lilos P; Kornreich L; Laron Z
J Pediatr Endocrinol Metab; 2009 Mar; 22(3):235-9. PubMed ID: 19492579
[TBL] [Abstract][Full Text] [Related]
9. Early structural status of the eyes of healthy term neonates conceived by in vitro fertilization or conceived naturally.
Axer-Siegel R; Herscovici Z; Davidson S; Linder N; Sherf I; Snir M
Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5454-8. PubMed ID: 18055792
[TBL] [Abstract][Full Text] [Related]
10. Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity).
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Clin Endocrinol (Oxf); 2006 Jul; 65(1):114-7. PubMed ID: 16817829
[TBL] [Abstract][Full Text] [Related]
11. [Variability of the eyeballs axial length in children with pseudophakia].
Filipek E; Koraszewska-Matuszewska B; Samochowiec-Donocik E; Nawrocka L; Pieczara E
Klin Oczna; 2006; 108(7-9):301-5. PubMed ID: 17290829
[TBL] [Abstract][Full Text] [Related]
12. Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency.
Silbergeld A; Lilos P; Laron Z
J Pediatr Endocrinol Metab; 2007 Dec; 20(12):1325-8. PubMed ID: 18341092
[TBL] [Abstract][Full Text] [Related]
13. The development of the refractive status and ocular growth in C57BL/6 mice.
Zhou X; Shen M; Xie J; Wang J; Jiang L; Pan M; Qu J; Lu F
Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5208-14. PubMed ID: 18689702
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic advances in growth hormone insensitivity.
David A; Metherell LA; Clark AJ; Camacho-Hübner C; Savage MO
Endocrinol Metab Clin North Am; 2005 Sep; 34(3):581-95, viii. PubMed ID: 16085161
[TBL] [Abstract][Full Text] [Related]
15. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome).
Ben-Dov I; Gaides M; Scheinowitz M; Wagner R; Laron Z
Clin Endocrinol (Oxf); 2003 Dec; 59(6):763-7. PubMed ID: 14974919
[TBL] [Abstract][Full Text] [Related]
16. Consequences of not treating children with laron syndrome (primary growth hormone insensitivity).
Laron Z
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1243-8; discussion 1261-2. PubMed ID: 11964019
[TBL] [Abstract][Full Text] [Related]
17. [Quality assurance in biometry before cataract surgery: which patients have an increased risk of aberrance from target refraction?].
Hayek S; Kniestedt C; Barthelmes D; Stürmer J
Klin Monbl Augenheilkd; 2007 Apr; 224(4):244-8. PubMed ID: 17458784
[TBL] [Abstract][Full Text] [Related]
18. Development and biological function of the female gonads and genitalia in IGF-I deficiency -- Laron syndrome as a model.
Laron Z
Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():188-91. PubMed ID: 16641857
[TBL] [Abstract][Full Text] [Related]
19. IGF-I treatment of patients with Laron syndrome suppresses serum thrombopoietin levels but does not affect serum erythropoietin.
Orit S; Joanne Y; Meira Z; Hannah T; Zvi L
Am J Hematol; 2009 Jan; 84(1):64. PubMed ID: 19021123
[No Abstract] [Full Text] [Related]
20. Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications.
Johnson TV; Toris CB; Fan S; Camras CB
J Glaucoma; 2008 Mar; 17(2):89-99. PubMed ID: 18344753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
